Financial Report: Johnson & Johnson

Johnson & Johnson

4Q Revenues: $18.1 billion (+2%)

4Q Earnings: $3.8 billion (+19%)

FY Revenues: $71.9 billion (+3%)

FY Earnings: $16.5 billion (+7%)

Comments: Worldwide Pharmaceutical sales were $33.5 billion for the year, up 7%. Domestic sales increased 10% and international sales increased 2%. Strong growth in new products include IMBRUVICA ($1.3 billion, up 82%), for use in treating certain B-cell malignancies; DARZALEX ($572 million), for the treatment of multiple myeloma; XARELTO ($2.3 billion, up 23%), an oral anticoagulant, and INVOKANA/INVOKAMET ($1.4 billion, up 8%) for the treatment of type 2 diabetes. Growth drivers also included STELARA ($3.2 billion, up 31%), REMICADE ($7.0 billion, up 6%), and SIMPONI/SIMPONI ARIA ($1.7 billion, up 31%), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; INVEGA SUSTENNA ($2.2 billion, up 21%) long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults and EDURANT ($573 million, up 40%) for the treatment of HIV. Sales were negatively impacted by generic competition for ORTHO TRI-CYCLEN LO, oral contraceptive and INVEGA (down 46% to $311 million), long-acting, injectable for the treatment of schizophrenia.